LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 47

Search options

  1. Article ; Online: Coronavirus Vaccine: Light at the End of the Tunnel.

    Ella, Krishna M / Mohan, V Krishna

    Indian pediatrics

    2020  Volume 57, Issue 5, Page(s) 407–410

    Abstract: The world is currently facing an unprecedented global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Predicting the next source of the pandemic can be very challenging. As vaccination is the best way to prevent an ... ...

    Abstract The world is currently facing an unprecedented global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Predicting the next source of the pandemic can be very challenging. As vaccination is the best way to prevent an infectious disease, the development of an effective vaccine against SARS-CoV-2 can not only reduce the morbidity and mortality associated with it, but can also lessen the economic impact. As the traditional method of vaccine development takes many years for a vaccine to be available to the society, the vaccine development for SARS-CoV-2 should be speeded up using a pandemic approach with fast-track approvals from the regulatory authorities. Various challenges associated with developing a vaccine during the pandemic such as technological hurdles, clinical development pathways, regulatory issues, and support from global funding agencies are expressed here.
    MeSH term(s) Betacoronavirus ; COVID-19 ; COVID-19 Vaccines ; Coronavirus Infections/prevention & control ; Drug Development ; Global Health ; Humans ; Pandemics/prevention & control ; Pneumonia, Viral/prevention & control ; Research Support as Topic ; SARS-CoV-2 ; Viral Vaccines
    Chemical Substances COVID-19 Vaccines ; Viral Vaccines
    Keywords covid19
    Language English
    Publishing date 2020-04-15
    Publishing country India
    Document type Journal Article
    ZDB-ID 402594-5
    ISSN 0974-7559 ; 0019-6061
    ISSN (online) 0974-7559
    ISSN 0019-6061
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Characterization of Lysophospholipase D Activity in Mammalian Cell Membranes.

    Xie, Yuhuan / Ella, Krishna M / Gibbs, Terra C / Yohannan, Marianne E / Knoepp, Stewart M / Balijepalli, Pravita / Meier, G Patrick / Meier, Kathryn E

    Cells

    2024  Volume 13, Issue 6

    Abstract: Lysophosphatidic acid (LPA) is a lipid mediator that binds to G-protein-coupled receptors, eliciting a wide variety of responses in mammalian cells. Lyso-phospholipids generated via phospholipase ... ...

    Abstract Lysophosphatidic acid (LPA) is a lipid mediator that binds to G-protein-coupled receptors, eliciting a wide variety of responses in mammalian cells. Lyso-phospholipids generated via phospholipase A
    MeSH term(s) Male ; Rats ; Humans ; Animals ; Female ; Apoptosis ; Cell Line, Tumor ; Ovarian Neoplasms ; Cell Membrane ; Mammals ; Phosphoric Diester Hydrolases
    Chemical Substances alkylglycerophosphoethanolamine phosphodiesterase (EC 3.1.4.39) ; Phosphoric Diester Hydrolases (EC 3.1.4.-)
    Language English
    Publishing date 2024-03-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2661518-6
    ISSN 2073-4409 ; 2073-4409
    ISSN (online) 2073-4409
    ISSN 2073-4409
    DOI 10.3390/cells13060520
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Coronavirus Vaccines: Light at the End of the Tunnel

    Ella, Krishna M. / Mohan, V. Krishna

    Indian pediatrics

    Abstract: The world is currently facing an unprecedented global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Predicting the next source of the pandemic can be very challenging As vaccination is the best way to prevent an ... ...

    Abstract The world is currently facing an unprecedented global pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Predicting the next source of the pandemic can be very challenging As vaccination is the best way to prevent an infectious disease, the development of an effective vaccine against SARS-CoV-2 can not only reduce the morbidity and mortality associated with it, but can also lessen the economic impact As the traditional method of vaccine development takes many years for a vaccine to be available to the society, the vaccine development for SARS-CoV-2 should be speeded up using a pandemic approach with fast-track approvals from the regulatory authorities Various challenges associated with developing a vaccine during the pandemic such as technological hurdles, clinical development pathways, regulatory issues, and support from global funding agencies are expressed here
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #60460
    Database COVID19

    Kategorien

  4. Article ; Online: Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern.

    Deshpande, Gururaj Rao / Yadav, Pragya D / Abraham, Priya / Nyayanit, Dimpal A / Sapkal, Gajanan N / Shete, Anita M / Gupta, Nivedita / Vadrevu, Krishna Mohan / Ella, Raches / Panda, Samiran / Bhargava, Balram

    Journal of travel medicine

    2022  Volume 29, Issue 3

    MeSH term(s) Antibodies, Neutralizing ; COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; Vaccines, Inactivated
    Chemical Substances Antibodies, Neutralizing ; COVID-19 Vaccines ; Vaccines, Inactivated
    Language English
    Publishing date 2022-03-23
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1212504-0
    ISSN 1708-8305 ; 1195-1982
    ISSN (online) 1708-8305
    ISSN 1195-1982
    DOI 10.1093/jtm/taac039
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees.

    Yadav, Pragya D / Sapkal, Gajanan N / Abraham, Priya / Ella, Raches / Deshpande, Gururaj / Patil, Deepak Y / Nyayanit, Dimpal A / Gupta, Nivedita / Sahay, Rima R / Shete, Anita M / Panda, Samiran / Bhargava, Balram / Mohan, V Krishna

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2021  Volume 74, Issue 2, Page(s) 366–368

    MeSH term(s) Antibodies, Neutralizing ; Antibodies, Viral ; Humans ; Neutralization Tests
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral
    Language English
    Publishing date 2021-05-10
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciab411
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin.

    Yadav, Pragya D / Sapkal, Gajanan N / Ella, Raches / Sahay, Rima R / Nyayanit, Dimpal A / Patil, Deepak Y / Deshpande, Gururaj / Shete, Anita M / Gupta, Nivedita / Mohan, V Krishna / Abraham, Priya / Panda, Samiran / Bhargava, Balram

    Journal of travel medicine

    2021  Volume 28, Issue 7

    MeSH term(s) Antibodies, Neutralizing ; COVID-19 ; COVID-19 Vaccines ; Humans ; SARS-CoV-2
    Chemical Substances Antibodies, Neutralizing ; COVID-19 Vaccines
    Language English
    Publishing date 2021-07-06
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1212504-0
    ISSN 1708-8305 ; 1195-1982
    ISSN (online) 1708-8305
    ISSN 1195-1982
    DOI 10.1093/jtm/taab104
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.

    Mohandas, Sreelekshmy / Yadav, Pragya D / Shete-Aich, Anita / Abraham, Priya / Vadrevu, Krishna Mohan / Sapkal, Gajanan / Mote, Chandrashekhar / Nyayanit, Dimpal / Gupta, Nivedita / Srinivas, Vellimedu Kannappa / Kadam, Manoj / Kumar, Abhimanyu / Majumdar, Triparna / Jain, Rajlaxmi / Deshpande, Gururaj / Patil, Savita / Sarkale, Prasad / Patil, Deepak / Ella, Raches /
    Prasad, Sai D / Sharma, Sharda / Ella, Krishna M / Panda, Samiran / Bhargava, Balram

    iScience

    2021  Volume 24, Issue 2, Page(s) 102054

    Abstract: The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 ... ...

    Abstract The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response.
    Language English
    Publishing date 2021-01-09
    Publishing country United States
    Document type Journal Article
    ISSN 2589-0042
    ISSN (online) 2589-0042
    DOI 10.1016/j.isci.2021.102054
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.

    Ganneru, Brunda / Jogdand, Harsh / Daram, Vijaya Kumar / Das, Dipankar / Molugu, Narasimha Reddy / Prasad, Sai D / Kannappa, Srinivas V / Ella, Krishna M / Ravikrishnan, Rajaram / Awasthi, Amit / Jose, Jomy / Rao, Panduranga / Kumar, Deepak / Ella, Raches / Abraham, Priya / Yadav, Pragya D / Sapkal, Gajanan N / Shete-Aich, Anita / Desphande, Gururaj /
    Mohandas, Sreelekshmy / Basu, Atanu / Gupta, Nivedita / Vadrevu, Krishna Mohan

    iScience

    2021  Volume 24, Issue 4, Page(s) 102298

    Abstract: We report the development and evaluation of safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel. We used a well-characterized SARS- ... ...

    Abstract We report the development and evaluation of safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel. We used a well-characterized SARS-CoV-2 strain and an established Vero cell platform to produce large-scale GMP-grade highly purified inactivated antigen. Product development and manufacturing process were carried out in a BSL-3 facility. Immunogenicity and safety were determined at two antigen concentrations (3μg and 6μg), with two different adjuvants, in mice, rats, and rabbits. Our results show that BBV152 vaccine formulations generated significantly high antigen-binding and neutralizing antibody titers (NAb), at both concentrations, in all three species with excellent safety profiles. The inactivated vaccine formulation contains TLR7/8 agonist adjuvant-induced Th1-biased antibody responses with elevated IgG2a/IgG1 ratio and increased levels of SARS-CoV-2-specific IFN-γ
    Language English
    Publishing date 2021-03-10
    Publishing country United States
    Document type Journal Article
    ISSN 2589-0042
    ISSN (online) 2589-0042
    DOI 10.1016/j.isci.2021.102298
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Genetic diversity of Chikungunya virus, India 2006-2010: evolutionary dynamics and serotype analyses.

    Sumathy, K / Ella, Krishna M

    Journal of medical virology

    2012  Volume 84, Issue 3, Page(s) 462–470

    Abstract: The genetic diversity of Chikungunya virus (CHIKV) causing recurring outbreaks in India since 2006 was studied. The 2006 epidemic was caused by a virus strain of the East, Central and South African (ECSA) genotype with 226A in the E1 glycoprotein. The ... ...

    Abstract The genetic diversity of Chikungunya virus (CHIKV) causing recurring outbreaks in India since 2006 was studied. The 2006 epidemic was caused by a virus strain of the East, Central and South African (ECSA) genotype with 226A in the E1 glycoprotein. The variant strain with E1-A226V mutation caused outbreaks since 2007 in the state of Kerala where Aedes albopictus is the abundant mosquito vector. Molecular epidemiology data since 2007 is scarce from other regions of the country. RT-PCR, sequencing and phylogenetic analyses of CHIKV isolates from the 2009 to 2010 epidemics in the States of Tamil Nadu and Andhra Pradesh placed them in a separate clade within the ECSA lineage. The isolates of the study had 226A in the E1 glycoprotein. The isolates had a novel E1-K211E mutation that was under significant positive selection. E1-211E is highly conserved in the Asian genotype of the virus circulated by Aedes aegypti. Unique mutations in E2 glycoprotein were identified. The two sub-lineages of ECSA genotype circulating in India parallel the abundance of Ae. albopictus and Ae. aegypti. Novel mutations in the envelope glycoproteins suggest adaptive evolution of the virus to local vector abundance. Cross neutralization of the virus isolates from recurring Indian epidemics indicated that no distinct serotypes had evolved. The study has provided insights into the origin, distribution and evolutionary adaptation of the virus to local vector abundance in the region that has reportedly, the highest incidence of CHIKV infection in the world.
    MeSH term(s) Alphavirus Infections/epidemiology ; Alphavirus Infections/virology ; Chikungunya virus/classification ; Chikungunya virus/genetics ; Disease Outbreaks ; Evolution, Molecular ; Genetic Variation ; India/epidemiology ; Mutation ; Phylogeny ; Selection, Genetic ; Serotyping/methods ; Viral Envelope Proteins/genetics
    Chemical Substances Viral Envelope Proteins
    Language English
    Publishing date 2012-03
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.23187
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation

    Brunda Ganneru / Harsh Jogdand / Vijaya Kumar Daram / Dipankar Das / Narasimha Reddy Molugu / Sai D. Prasad / Srinivas V. Kannappa / Krishna M. Ella / Rajaram Ravikrishnan / Amit Awasthi / Jomy Jose / Panduranga Rao / Deepak Kumar / Raches Ella / Priya Abraham / Pragya D. Yadav / Gajanan N. Sapkal / Anita Shete-Aich / Gururaj Desphande /
    Sreelekshmy Mohandas / Atanu Basu / Nivedita Gupta / Krishna Mohan Vadrevu

    iScience, Vol 24, Iss 4, Pp 102298- (2021)

    2021  

    Abstract: Summary: We report the development and evaluation of safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel. We used a well- ... ...

    Abstract Summary: We report the development and evaluation of safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel. We used a well-characterized SARS-CoV-2 strain and an established Vero cell platform to produce large-scale GMP-grade highly purified inactivated antigen. Product development and manufacturing process were carried out in a BSL-3 facility. Immunogenicity and safety were determined at two antigen concentrations (3μg and 6μg), with two different adjuvants, in mice, rats, and rabbits. Our results show that BBV152 vaccine formulations generated significantly high antigen-binding and neutralizing antibody titers (NAb), at both concentrations, in all three species with excellent safety profiles. The inactivated vaccine formulation contains TLR7/8 agonist adjuvant-induced Th1-biased antibody responses with elevated IgG2a/IgG1 ratio and increased levels of SARS-CoV-2-specific IFN-γ+ CD4+ T lymphocyte response. Our results support further development for phase I/II clinical trials in humans.
    Keywords Immune Response ; Immunology ; Virology ; Science ; Q
    Subject code 570
    Language English
    Publishing date 2021-04-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top